Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Jul 28;13(1):12255.
doi: 10.1038/s41598-023-39386-x.

Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

B Trevisan  1 , F F Pepe  1 , I Vallini  2 , E Montagna  3 , D Amoroso  4 , R Berardi  5 , A Butera  6 , K Cagossi  7 , L Cavanna  8 , M Ciccarese  9 , S Cinieri  10 , E Cretella  11 , E De Conciliis  12 , A Febbraro  13 , F Ferraù  14 , A Ferzi  15 , A Baldelli  16 , A Fontana  17 , A R Gambaro  18 , O Garrone  19 , V Gebbia  20 , D Generali  21 , L Gianni  22 , F Giovanardi  23 , A Grassadonia  24 , V Leonardi  25 , S Sarti  26 , A Musolino  27 , M Nicolini  22 , C Putzu  28 , F Riccardi  29 , D Santini  30 , M G Sarobba  31 , M G Schintu  32 , G Scognamiglio  33 , P Spadaro  34 , C Taverniti  35 , D Toniolo  36 , P Tralongo  37 , A Turletti  38 , R Valenza  39 , M R Valerio  40 , P Vici  41 , L Clivio  42 , V Torri  42 , M E Cazzaniga  43 ; VICTOR Study Group
Affiliations
Observational Study

Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

B Trevisan et al. Sci Rep. .

Abstract

Nowadays, treatment of metastatic breast cancer (MBC) has been enriched with novel therapeutical strategies. Metronomic chemotherapy (mCHT) is a continuous and frequent administration of chemotherapy at a lower dose and so whit less toxicity. Thus, this strategy could be attractive for elderly MBC patients. Aim of this analysis is to provide insights into mCHT's activity in a real-life setting of elderly MBC patients. Data of patients ≥ 75 years old included in VICTOR-6 study were analyzed. VICTOR-6 is a multicentre, Italian, retrospective study, which collected data on mCHT in MBC patients treated between 2011 and 2016. A total of 112 patients were included. At the beginning of mCHT, median age was 81 years (75-98) and in 33% of the patients mCHT was the first line choice. Overall Response Rate (ORR) and Disease Control Rate (DCR) were 27.9% and 79.3%, respectively. Median PFS ranged between 7.6 and 9.1 months, OS between 14.1 and 18.5 months. The most relevant toxicity was the hematological one (24.1%); severe toxicity (grade 3-4) ranged from 0.9% for skin toxicity up to 8% for hematologic one. This is a large study about mCHT in elderly MBC patients, providing insights to be further investigated in this subgroup of frail patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
CONSORT flow chart.
Figure 2
Figure 2
Percentages of patients receiving single agents mCHT.
Figure 3
Figure 3
PFS by type of mCHT treatment.
Figure 4
Figure 4
PFS according to the line of mCHT treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cardoso F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) Ann. Oncol. 2018;29:1634–1657. doi: 10.1093/annonc/mdy192. - DOI - PMC - PubMed
    1. de Iuliis F, Salerno G, Taglieri L, Lanza R, Scarpa S. On and off metronomic oral vinorelbine in elderly women with advanced breast cancer. Tumori. 2015;101:30–35. doi: 10.5301/tj.5000207. - DOI - PubMed
    1. Cazzaniga ME, et al. Pan-European expert meeting on the use of metronomic chemotherapy in advanced breast cancer patients: The PENELOPE project. Adv. Ther. 2019;36:381–406. doi: 10.1007/s12325-018-0844-4. - DOI - PubMed
    1. Douglas H, Bergers G, Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 2000;105:1045–1047. doi: 10.1172/JCI9872. - DOI - PMC - PubMed
    1. Romiti A, Falcone R, Roberto M, Marchetti P. Current achievements and future perspectives of metronomic chemotherapy. Investig. New Drugs. 2017;35:359–374. doi: 10.1007/s10637-016-0408-x. - DOI - PubMed

Publication types